57 results about "Malignant Neoplastic Disease" patented technology

The present invention provides compounds of the following structure, wherein R₁, R₂, R₄, R_4′, R₆, R₇, and R₁₅ are defined above:

These compounds are useful in treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders. The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.

Compounds of formula I are provided, wherein R₁-R₉ and n are defined herein, and pharmaceutical compositions and kits containing these compounds.

Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I or formula II, wherein R₃-R₅, R₁₀, and R₁₁ are defined herein.

Compounds of formula I, wherein R₁-R₉ and n are defined herein, and pharmaceutical compositions and kits containing these compounds are provided.

Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I or formula II, wherein R₃-R₅, R₁₀, and R₁₁ are defined herein.

Compounds of formula I or II are provided, wherein R₁—R₈ are defined herein, and pharmaceutical compositions and kits containing these compounds.

Also provides are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I, formula II, or formula III, wherein R₂—R₄ and R₉ are defined herein.

Compositions, preferably pharmaceutical compositions, containing micronized tanaproget, or pharmaceutically acceptable salt thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, butylated hydroxyanisole, povidone, and magnesium stearate, are provided. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.

A method for designing and synthesizing 7-azaindirubin and 7-azaisoindigo derivative and its medicinal use are disclosed. It changes indirubin and isoindigo nuclear-parent molecule atomic composition to form into compound. It also changes original molecule electric property. The process is carried out by coupling at different position by 7-azaindole and indole bi-molecule, inhibiting CDKs and CDKIs growth and breed and inducing CDKIs biological function. It can be used to treat malignant tumor, HIV and nervous system diseases.

The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.

The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate; or can contain microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, povidone, and magnesium stearate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefore Additional uses include stimulation of food intake.

The present invention relates to a medicine for curing malignant tumor and its preparation method. It is made of asparagus tuber, Buddha's hand fruit, American ginseng, acanthopanax obovatus, hippophae rhmnoides fruit, Chinese gooseberry root, venom and bolbostemma tuber as raw material through the processes of removing dust and cleaning, decocting, alcohol precipitation extraction and alcohol impregnating extraction. Said medicine has no toxic side effect, has strong action of resisting tumor and raising immunity of body, and can possess synergistic action and attenuation when it is matched with radiotherapy and chemical medicine therapy to cure malignant tumor, and can obtain good therapeutic effect.

This invention provides compositions and methods for stimulating the immune system. Such methods include administering an extract, purified peptide-linked glucan or active component thereof from Coriolus versicolor. The methods are particularly useful for prophylactic and therapeutic treatment of secondary immunodeficiency, wherein the immunodeficiency is the result of an infection, a malignant neoplastic disease, an autoimmune disease, a protein losing state, an immunosuppressive treatment, surgery or anesthesia.

The present invention relates to chimeric molecules comprising an oligonucleotide complementary to a region of the ribonucleotide component of telomerase attached to an activator of RNase L ("activator-antisense complex") which specifically cleaves the ribonucleotide portion of a telomerase enzyme. The present invention relates to methods of inhibiting telomerase enzymatic activity with activator-antisense complexes targeted to the RNA component of telomerase. The present invention further relates to methods of treating malignant neoplastic disease, wherein the malignant cells contain a telomerase activity that is necessary for the growth of the malignant cells.

Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.

The invention belongs to the technical field of immunology and biology and particularly relates to a detection kit for a blood serum PSMD4 protein and a detection method for the blood serum PSMD4 protein and application of the detection kit. The ELISA detection kit and detection method for the PSMD4 protein, provided by the invention, can be applied to the serological diagnosis and tumor screening of a variety of malignant tumors, particularly lung cancer, gastric cancer and colon cancer. According to the detection kit, the detection method and the application, the operation is simple and convenient, the content of the PSMD4 protein in blood serum of malignant tumor patients can be detected in an accurate and high-sensitivity manner, and thus, a new means and a method are provided for clinical checking and fundamental researches.

The invention provides a breast cancer histopathological type classification method based on generative adversarial network screening image blocks, which comprises the following steps: acquiring a breast cancer histopathological type image data set, and further comprises the following steps: preprocessing breast cancer histopathological type images; enabling the generative adversarial network to screen normal regions in the benign image blocks and the malignant image blocks; enabling the generative adversarial network to screen benign regions in the malignant image blocks; and classifying thebreast cancer histopathological images by using a convolutional neural network based on cyclic dense connection. According to the invention, the improved unsupervised generative adversarial network isadopted to learn the data distribution of the normal pathology image and the benign tumor pathology image respectively, so that the benign tumor area and the normal area in the malignant tumor pathology image and the normal area in the benign tumor pathology image can be screened; and the possibility is provided for assisting doctors to diagnose the illness state more accurately and more quicklyto the maximum extent.

The present invention relates to the technical field of functional food products, specifically novel functional food products for the treatment and/or prevention of malignant neoplastic diseases of the human or animal body, and to methods for manufacturing such functional food products.

The invention provides a compound, which is obtained by splicing a heptamethine cyanine structure and an epidermal growth factor receptor(EGFR) targeted drug molecular structure. The compound providedby the invention can be used as a hypoxia and EGFR double-targeted near infrared fluorescence probe, can realize the purpose of accurate imaging on malignant tumor lesions with high EGFR expression by targeting the tumor marker EGFR and the hypoxia state of tumor cells; in addition, the compound provided by the invention can be used as a photosensitizer for cancer treatment.

In an effort to discover therapies for treating HSP70 related diseases, a previously unidentified hydrophobic pocket was found in the C-terminal domain of DnaK and of human HSP70. A novel chemical scaffold was also discovered for identifying compounds that treat diseases related to this hydrophobic pocket. The compounds have the structure of the formula (I), wherein L, M, and R¹-R⁵ are defined herein and are, therefore, in these therapies, optionally with other pharmaceutical agents such as genotoxic agents. Accordingly these compounds are useful in inhibiting HSP70 or DnaK, reducing HSP70 in mitochondria of a cancer cell, treating malignant neoplastic disease, or inhibiting or reducing bacterial growth. These compounds also resulted in novel methods of screening for a HSP70 inhibitor or DnaK inhibitor by using the three-dimensional structure of the hydrophobic pocket in DnaK or HSP70.

The invention discloses a nasopharyngeal carcinoma positioning segmentation method and system based on an image segmentation convolutional neural network, and the method comprises the steps: obtaining an electronic nose endoscopic image through employing a WLI mode and an NBI mode, inputting the electronic nose endoscopic image into a nasopharyngeal carcinoma diagnosis model based on the image segmentation convolutional neural network, obtaining a malignant tumor region marked by the diagnosis model, and carrying out the positioning segmentation of the nasopharyngeal carcinoma. The diagnosis system can judge the captured image in real time, mark the malignant tumor part in the nasopharyngeal carcinoma image, export the diagnosis result, intuitively judge whether the target lesion is the malignant tumor tissue or not and determine the boundary range of the malignant tumor lesion according to the malignant tumor lesion as long as the lens is focused on the suspicious lesion tissue in the nasopharyngeal cavity. Suspicious diseased regions are quickly selected for biopsy, so that the accuracy of nasopharyngeal carcinoma detection under a nasal endoscope is effectively improved, and the detection rate of biopsy is increased.

The invention discloses a method for assessing a cancer radiotherapy and chemotherapy standard conforming degree. The method includes the following steps: firstly, defining an assessment model of the cancer radiotherapy and chemotherapy standard conforming degree, secondly, formulating executing rules of difference assessment of radiotherapy and chemotherapy operation standards and difference assessment of chemotherapy drug use and radiation dosage use, enabling an assessor to respectively assess whether radiotherapy and chemotherapy processes of a certain patient conform to the radiotherapy and chemotherapy operation standards and chemotherapy drug use and radiation dosage standards or not, then, formulating a multi-level itemizing weighting rule so as to grade a total standard conforming degree of the radiotherapy and chemotherapy processes of the cancer patient, finally, taking corresponding measures on patient diagnosis and treatment based on the score, enabling a therapeutic schedule with the score lower than a veto threshold value and drug use with the score lower than a veto threshold value to be refused, and enabling a therapeutic schedule with the score higher than a standard-conforming threshold value and drug use with the score higher than a standard-conforming threshold value to be accurately submitted and applied. According to the method for assessing the cancer radiotherapy and chemotherapy standard conforming degree, the appearing probability of non-standard operations and non-standard drug use in the cancer radiotherapy and chemotherapy processes can be reduced.